Clinical Trial Update: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (Ruxo-BEAT) evaluating ruxolitinib in high-risk polycythemia vera or high-risk essential thrombocythemia; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: RWTH Aachen University | Conditions: Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Status: ACTIVE_NOT_RECRUITING